Skip to main content

AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy

 February 16, 2021 09:15 ET

OCALA, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, a critical step in the company’s ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.

Earlier this year, the company announced that it had entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the proposed AMP-COV-100 (CHDR2049) trial. Last week, approval was received from the Dutch local Ethics Committee, clearing the road for execution of the trial.

The current study plans call for the enrollment of eight healthy subjects in each of four Ampligen treatment groups and eight placebo subjects, for a total of 40 healthy subjects. This will assess the safety, tolerability and biological activity of repeated administration of Ampligen intranasally. The subjects will receive intranasal dosing every other day for 13 days, for a total of seven doses each. AIM is funding the clinical study.

“We are delighted and honored to receive Ethics Committee approval, an important step toward initiation of the trial,” said AIM CEO Thomas K. Equels. “We are on track for site initiation later this month and expect to begin enrolling participants in the study during the first quarter of 2021. Importantly, our prior in vitro modeling at The Institute for Antiviral Research at Utah State University demonstrated that Ampligen was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage concentrations. As a result, we are highly encouraged by the potential of an intranasal prophylactic approach using Ampligen to prevent infection and spread of COVID-19 and are excited to commence safety tests of potential dosing regimens.”

Dr. Matthijs Moerland, principal investigator at CHDR: “We’re very happy helping AIM with this important step. Together with AIM’s study team, we feel we have not only designed a trial evaluating Ampligen’s intranasal safety profile, but also yielding important mechanistic data on the compound’s immunomodulatory activities.”

Popular Posts in the Last 7 Days

Perplexity A.I. wrote this op-ed about Rebecca Culshaw's Substack

" A new study finds that prior herpesvirus infections are linked to a faster age-related increase in blood biomarkers associated with dementia, even in cognitively healthy women. Researchers measured five key biomarkers in 167 women and found that seropositivity for HHVs doubled the rate of biomarker accumulation compared to those without prior infection. The strongest viral associations were seen for Epstein-Barr virus and HHV6, with amyloid-beta and phosphorylated tau levels most affected. These findings support the hypothesis that chronic viral infections may accelerate neurodegeneration and raise dementia risk independently of genetic factors."

Twenty Potential Mistakes Leading to the Misidentification of HIV as the Cause of AIDS

The Perils of Diagnostic Totalitarianism: The Case of AIDS Nosology

African Swine Fever and Kaposi's Sarcoma

Popular Post in the Last 30 Days

Consciousness of Guilt in Science and Medicine (From Perplexity A.I.)

We asked Perplexity A.I. to make the argument that Castleman's Disease undermines the nosology, epidemiology, and virology of AIDS.

If one studies all the medical literature on Chronic Fatigue Syndrome and AIDS, what viruses, infections, and pathological findings do they have in common? (From Perplexity)

HHV-6 in K.S. and AIDS

If the nosological definition of AIDS is reset to include all illnesses with serious inflammation regardless of HIV positivity or status, what illnesses could be included in the nosology of AIDS?

Popular Posts from the Last Year

Oral Kaposi's Sarcoma looks like the Crimson Crescents in Chronic Fatigue Syndrome patients.

Dr. Bhupesh Prusty and Professor Thomas Rudel discuss their HHV-6 research

Dr. Rebecca Culshaw Smith's book is discussed on Twitter

Ablashi discusses HHV-6, AIDS, Alzheimer's, and Chronic Fatigue Syndrome

Is African Swine Fever a threat to human health in Congo?

All Time Most Popular Posts

Dr. Bhupesh Prusty and Professor Thomas Rudel discuss their HHV-6 research

Anthony Fauci was part of the gang that silenced and destroyed Judy Mikovits.

Was Judy Mikovits destroyed because her XMRV work would have ultimately shown HIV is a total fraud?

Is Chronic Fatigue Syndrome the other AIDS epidemic in the gay community?